Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival

Published:2019-06 Issue:6 Volume:70 Page:1262-1277
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Llovet Josep M.^ORCID,Montal Robert,Villanueva Augusto^ORCID

Funder

European Commission

US Department of Defense

National Cancer Institute

Spanish National Health Institute

Cancer Research UK

Samuel Waxman Cancer Research Foundation

Generalitat de Catalunya

Tisch Cancer Institute

FSEOM

Publisher

Elsevier BV

Subject

Hepatology

Reference131 articles.

1. Global cancer statistics, 2012;Torre;CA Cancer J Clin,2015

2. Hepatocellular carcinoma;Llovet;Nat Rev Dis Prim,2016

3. Prognosis of hepatocellular carcinoma: the BCLC staging classification;Llovet;Semin Liver Dis,1999

4. EASL clinical practice guidelines: management of hepatocellular carcinoma;Galle;J Hepatol,2018

5. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival;Llovet;Hepatology,2003

Cited by 165 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic Therapies for Hepatocellular Carcinoma in India;Journal of Clinical and Experimental Hepatology;2024-11

2. Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2024-09

3. Efficacy of doxorubicin and lipiodol therapy by trans-arterial chemoembolization in hepatocellular carcinoma Egyptian patients and relation to genetic polymorphisms;Expert Review of Anticancer Therapy;2024-08-21

4. RECIST 1.1, mRECIST, and Choi criteria for evaluating treatment response and survival outcomes in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab;European Radiology;2024-07-30

5. Measures for response assessment in HCC treatment;Hepatoma Research;2024-07-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3